Latest Regulatory Filings News

LTR Pharma has wrapped up recruitment for its SPONTAN Phase II pharmacokinetic study, with interim results expected soon to bolster FDA approval efforts. Meanwhile, US commercial talks for ROXUS advance cautiously under the FDA 503(a) personalised medicine pathway.

Echo IQ has taken a major step in its US expansion by deploying its AI-powered EchoSolv AS software at Mount Sinai Health System, one of America’s leading cardiovascular centres. This marks a key milestone in integrating AI into routine cardiology workflows at scale.

Cleo Diagnostics has kicked off a staged manufacturing program with Bio-Techne to produce ovarian cancer test kits, moving from clinical sample collection to analytical validation and FDA submission preparation.

Paradigm Biopharmaceuticals has upsized a $14 million placement and launched a $2 million SPP, boosting its cash runway to around $45 million. This capital injection supports the ongoing Phase 3 trial for knee osteoarthritis, with interim results expected in Q3 2026.

Imricor Medical Systems updates its SEC Form 10 with minor SEC-driven revisions as it pushes forward with FDA clearances and clinical trials, reporting a $25.3 million net loss in 2025 amid early-stage commercialisation.

Kinetiko Energy has unveiled a staged gas production strategy in South Africa, aiming for initial compressed natural gas revenues by Q2/Q3 2027. The company’s new Rolling Cluster Development Strategy promises a risk-managed, capital-efficient pathway from early CNG production to full-field LNG.

Multistack International is progressing with the sale of its core assets to Willing Y Limited, maintaining operations cautiously while cash reserves decline amid ongoing operating losses.

Nova Minerals has secured ASIC registration of its Scheme Booklet for re-domiciling to the US, alongside amendments to warrant terms that triple warrant exchange ratios ahead of the move.

Taiton Resources has completed a partial placement of 9.55 million shares to sophisticated investors, extending related option expiry dates to June 2029. A further tranche awaits due to delayed funds, while the company continues to advance exploration projects across South Australia and New South Wales.

Noxopharm reports preclinical data revealing SOF-SKN’s active ingredient remains in skin tissues for about 3.5 days with minimal systemic absorption, supporting less frequent dosing and sustained activity for cutaneous lupus treatment.

SSH Group Ltd reported a 44% reduction in hire purchase debt alongside $48.4 million in rolling 12-month cash receipts, while progressing high-grade drilling and mining operations at Wagtail and Gold Duke projects.

Memphasys Limited has marked a milestone quarter with revenue surpassing A$100,000, driven by repeat orders and multi-year contracts, signalling its transition to a commercially focused biotech business.